DDInter802 DDInter596
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Galantamine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Galantamine {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Galantamine {u} (Compound) causes {v} (Side Effect) Anxiety
Anxiety {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Galantamine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Galantamine {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Galantamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Doxorubicin (Compound)
Galantamine (Compound) upregulates STK10 (Gene) and STK10 (Gene) is upregulated by Doxorubicin (Compound)
Galantamine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Doxorubicin (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Galantamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound) and Idarubicin (Compound) resembles Doxorubicin (Compound)
Galantamine (Compound) upregulates STK10 (Gene) and STK10 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin (Compound) resembles Doxorubicin (Compound)